Globus Medical and Medtronic have both outperformed the medical device industry over the past year, but Globus Medical shows stronger momentum and higher short-term upside. Globus Medical posted 27% year-over-year revenue growth in the first quarter, driven by double-digit gains in U.S. Spine and a 30.4% increase in Trauma, while Medtronic reported 9.9% revenue growth in its fiscal fourth quarter, supported by its Surgical & Endoscopy and Acute Care & Monitoring segments. Globus Medical remains debt-free with $560.9 million in cash and generated $202.4 million in operating cash flow, whereas Medtronic holds $9.2 billion in cash and investments but carries long-term debt after issuing $1.75 billion and repaying $2.93 billion in fiscal 2026. Based on analyst price targets, Globus Medical's average target of $109.83 implies a 29.75% upside, compared to Medtronic's average target of $96.96 representing a 20.42% increase. Zacks Investment Research rates Globus Medical a Buy and Medtronic a Sell, favoring the higher-growth, debt-free company for investors seeking stronger returns.
Globus MedicalGlobus Medical posted 27% revenue growth, is debt-free with strong cash, and has higher analyst upside potential.
Medtronic PLCMedtronic reported lower revenue growth (9.9%), carries long-term debt, and is rated Sell by Zacks with lower upside.